
1. Nutrients. 2017 Jul 18;9(7). pii: E767. doi: 10.3390/nu9070767.

Dose-Dependent Prebiotic Effect of Lactulose in a Computer-Controlled In Vitro
Model of the Human Large Intestine.

Bothe MK(1), Maathuis AJH(2), Bellmann S(3), van der Vossen JMBM(4), Berressem
D(5), Koehler A(6), Schwejda-Guettes S(7), Gaigg B(8), Kuchinka-Koch A(9), Stover
JF(10).

Author information: 
(1)Fresenius Kabi Deutschland GmbH, Else-Kroener-Strasse 1, 61352 Bad Homburg,
Germany. melanie.bothe@fresenius-kabi.com.
(2)Triskelion B.V., A TNO Company, P.O. Box 844, 3700 AV Zeist, The Netherlands. 
annet.maathuis@triskelion.nl.
(3)Triskelion B.V., A TNO Company, P.O. Box 844, 3700 AV Zeist, The Netherlands. 
susann.bellmann@triskelion.nl.
(4)The Netherlands Organisation for Applied Scientific Research (TNO),
Microbiology and Systems Biology Department, P.O. Box 360, 3700 AJ Zeist, The
Netherlands. jos.vandervossen@tno.nl.
(5)Fresenius Kabi Deutschland GmbH, Borkenberg 14, 61440 Oberursel, Germany.
dirk.berressem@fresenius-kabi.com.
(6)Fresenius Kabi Deutschland GmbH, Borkenberg 14, 61440 Oberursel, Germany.
annalena.koehler@fresenius-kabi.com.
(7)Fresenius Kabi Deutschland GmbH, Borkenberg 14, 61440 Oberursel, Germany.
susann.schwejda-guettes@fresenius-kabi.com.
(8)Fresenius Kabi Austria GmbH, Estermannstrasse 17, 4020 Linz, Austria.
barbara.gaigg@fresenius-kabi.com.
(9)Fresenius Kabi Austria GmbH, Estermannstrasse 17, 4020 Linz, Austria.
angelika.kuchinka-koch@fresenius-kabi.com.
(10)Fresenius Kabi Deutschland GmbH, Borkenberg 14, 61440 Oberursel, Germany.
john.stover@fresenius-kabi.com.

Lactulose, a disaccharide of galactose and fructose, used as a laxative or
ammonia-lowering drug and as a functional food ingredient, enhances growth of
Bifidobacterium and Lactobacillus at clinically relevant dosages. The prebiotic
effect of subclinical dosages of Lactulose, however, remains to be elucidated.
This study analyses changes in the microbiota and their metabolites after a 5
days Lactulose treatment using the TIM-2 system, a computer-controlled model of
the proximal large intestine representing a complex, high density, metabolically 
active, anaerobic microbiota of human origin. Subclinical dosages of 2-5 g
Lactulose were used. While 2 g Lactulose already increased the short-chain fatty 
acid levels of the intestinal content, 5 g Lactulose were required daily for 5
days in this study to exert the full beneficial prebiotic effect consisting of
higher bacterial counts of Bifidobacterium, Lactobacillus, and Anaerostipes, a
rise in acetate, butyrate and lactate, as well as a decrease in branched-chain
fatty acids, pH (suggested by an increase in NaOH usage), and ammonia.

DOI: 10.3390/nu9070767 
PMCID: PMC5537881
PMID: 28718839  [Indexed for MEDLINE]

Conflict of interest statement: M.B., D.B., S.S.-G., A.K., B.G., A.K.-K. and J.S.
are employees of Fresenius Kabi, the founding sponsor of this study.

